Nan Fung Life Sciences
Brian Mills, PhD, joined Pivotal Life Sciences in 2022. Prior to Pivotal, he was a research analyst at Jefferies covering the biotechnology sector, with a focus on neuroscience, psychiatry, precision medicine, IBD, microbiome, and orphan disease. His work integrated computational tools to derive insights into the space. Prior to Jefferies, Brian was a postdoctoral scholar at Stanford University where he studied neurological disease, including Alzheimer’s disease, Huntington’s disease, chronic fatigue syndrome, and traumatic brain injury. His PhD focused on developing translational biomarkers linking clinical and pre-clinical models of developmental disorders, including Autism and ADHD. He earned his PhD in neuroscience from Oregon Health and Science University (OHSU) and has published over 20 peer reviewed articles in top journals including the Journal of Neuroscience and PNAS.
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.